



Acquisition of Acton Pharmaceuticals completed

On August 30th, 2013, Meda announced the acquisition of Acton Pharmaceuticals, Inc. and its proprietary product Aerospan. The acquisition has now been completed. The purchase price for Acton amounted to 135 MUSD, on a cash and debt free basis. In addition, there is a milestone payment of 10 million USD and royalty based milestones.

About Aerospan

Aerospan (flunisolide HFA, 80 mcg) is approved by the U.S. Food and Drug Administration ("FDA") for the treatment of asthma in adult and pediatric patients 6 years of age and older. Aerospan is the first and only product registered in the US market with a built-in inhalation chamber (called a "spacer") which assists in the delivery of the medicine to the lungs.

"Aerospan gives us a unique opportunity to expand our product portfolio in one of our focus areas - Respiratory. We will generate interesting marketing synergies with Aerospan, especially in the world's biggest pharmaceutical market, the US", says Dr. Jörg-Thomas Dierks, CEO of Meda AB. "This is an important contribution to Meda's effort to strengthen our global position in the Respiratory area".

For further inquiries, please contact:

Anders Larnholt, Vice President Corporate Development & IR ph: +46 709-458 878
anders.larnholt@meda.se

Paula Treutiger, Investor Relations ph: +46 733-666 599
paula.treutiger@meda.se

MEDA AB (publ) is a leading international specialty pharma company. Meda's products are sold in more than 120 countries worldwide and the company is represented by its own organizations in over 55 countries. The Meda share is listed under Large Cap on the Nasdaq OMX Nordic Stock Exchange in Stockholm. Find out more, visit www.meda.se.

Forward-looking statements

This press release is not an offer to sell or a solicitation to buy shares in Meda. This press release also contains certain forward-looking statements with respect to certain future events and Meda's potential financial performance. These forward-looking statements can be identified by the fact that they do not relate only to historical or current facts, and may sometimes include words such as "may", "will", "seek", "anticipate", "expect", "estimate", "intend", "plan", "forecast", "believe" or other words of similar meaning. These forward looking statements reflect the current expectations on future events of the management at the time such statements are made, but are made subject to a number of risks and uncertainties. In the event such risks or uncertainties materialize, Meda's results could be materially affected. The risks and uncertainties include, but are not limited to, risks associated with the inherent uncertainty of pharmaceutical research and product development, manufacturing and commercialization, the impact of competitive products, patents, legal challenges, government regulation and approval, Meda's ability to secure new products for commercialization and/or development and other risks and uncertainties detailed from time to time in Meda AB's interim or annual reports, prospectuses or press releases. Listeners and readers are cautioned that no forward-looking statement is a guarantee of future performance and that actual result could differ materially from those contained in the forward-looking statements. Meda does not intend, nor undertakes, to update any such forward looking statements.